{"id":"tp-58353","type":"article-newspaper","title":"CNS Pharmaceuticals Posts $0.24 Q3 Loss Per Share as Cash Reaches $17.2M","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/58353","datePublished":"2026-11-16T13:03:30.000Z","dateModified":"2026-11-16T13:03:30.000Z","language":"en","abstract":"Cash and cash equivalents were $17.2 million at Sept. 30, up from $7.2 million at the end of 2025. The company believes its existing cash can fund planned operations beyond 12 months.","section":"Business","references":[]}